Glomerulonephritis (GN) encompasses a group of immune-mediated kidney disorders characterized by inflammation of the glomeruli, the kidney’s primary filtering units. Without timely and appropriate treatment, GN can lead to progressive kidney damage, chronic kidney disease, and eventual kidney failure. At International Modern Hospital (IMH), immunosuppressive therapy for GN is delivered through a structured, biopsy-guided, nephrology-led approach focused on disease control while minimizing treatment-related risks.

Immunosuppressive therapy is indicated in selected forms of GN where immune activation plays a central role in kidney injury. These include conditions such as rapidly progressive glomerulonephritis, membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis, lupus nephritis, and vasculitis-associated GN. Accurate diagnosis is essential, and kidney biopsy remains the gold standard for determining disease subtype, severity, and activity.

At IMH, treatment plans are individualized based on biopsy findings, disease progression, patient age, comorbidities, and risk of complications. Common immunosuppressive agents include corticosteroids, calcineurin inhibitors, antimetabolites, alkylating agents, and targeted biologic therapies. These medications aim to suppress immune-mediated inflammation, reduce proteinuria, and preserve kidney function.

Close monitoring is a critical component of therapy. Patients undergo regular laboratory testing to assess kidney function, immune response, medication levels, and potential side effects such as infections, metabolic disturbances, and bone marrow suppression. Nephrologists adjust therapy dynamically to maintain disease remission while reducing long-term toxicity.

Supportive care runs parallel to immunosuppression. Blood pressure control, renin-angiotensin system blockade, dietary modifications, and infection prevention strategies are integrated into care. Vaccination status is reviewed and optimized before initiating immunosuppressive therapy.

Family Medicine physicians play an essential role in ongoing care by monitoring overall health, managing comorbid conditions, reinforcing medication adherence, and providing early detection of treatment-related complications. This integrated model ensures continuity beyond specialty clinics.

Through precise diagnosis, personalized immunosuppressive regimens, and vigilant follow-up, IMH provides safe and effective treatment for patients with glomerulonephritis, aiming to achieve sustained remission and long-term kidney preservation.